Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

Rami S. Komrokji; Uwe Platzbecker; Pierre Fenaux; Amer M. Zeidan; Guillermo Garcia-Manero; Ghulam J. Mufti; Valeria Santini; María Díez-Campelo; Carlo Finelli; Joseph G. Jurcic; Peter L. Greenberg; Mikkael A. Sekeres; Amy E. DeZern; Michael R. Savona; Jeevan K. Shetty; Rodrigo Ito; George Zhang; Xianwei Ha; Jay T. Backstrom; Amit Verma

doi:10.1038/s41375-022-01521-4

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

Rami S. Komrokji
, Uwe Platzbecker
, Pierre Fenaux
, Amer M. Zeidan
, Guillermo Garcia-Manero
, Ghulam J. Mufti
, Valeria Santini
, María Díez-Campelo
, Carlo Finelli
, Joseph G. Jurcic
, Peter L. Greenberg
, Mikkael A. Sekeres
, Amy E. DeZern
, Michael R. Savona
, Jeevan K. Shetty
, Rodrigo Ito
, George Zhang
, Xianwei Ha
, Jay T. Backstrom
, Amit Verma

Oncology

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Original language	English (US)
Pages (from-to)	1432-1435
Number of pages	4
Journal	Leukemia
Volume	36
Issue number	5
DOIs	https://doi.org/10.1038/s41375-022-01521-4
State	Published - May 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-022-01521-4

Cite this

Komrokji, R. S., Platzbecker, U., Fenaux, P., Zeidan, A. M., Garcia-Manero, G., Mufti, G. J., Santini, V., Díez-Campelo, M., Finelli, C., Jurcic, J. G., Greenberg, P. L., Sekeres, M. A., DeZern, A. E., Savona, M. R., Shetty, J. K., Ito, R., Zhang, G., Ha, X., Backstrom, J. T., & Verma, A. (2022). Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia, 36(5), 1432-1435. https://doi.org/10.1038/s41375-022-01521-4

Komrokji, RS, Platzbecker, U, Fenaux, P, Zeidan, AM, Garcia-Manero, G, Mufti, GJ, Santini, V, Díez-Campelo, M, Finelli, C, Jurcic, JG, Greenberg, PL, Sekeres, MA, DeZern, AE, Savona, MR, Shetty, JK, Ito, R, Zhang, G, Ha, X, Backstrom, JT & Verma, A 2022, 'Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis', Leukemia, vol. 36, no. 5, pp. 1432-1435. https://doi.org/10.1038/s41375-022-01521-4

@article{7f59fee5fff948d8a5db9676ae7c8f05,

title = "Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis",

author = "Komrokji, \{Rami S.\} and Uwe Platzbecker and Pierre Fenaux and Zeidan, \{Amer M.\} and Guillermo Garcia-Manero and Mufti, \{Ghulam J.\} and Valeria Santini and Mar{\'i}a D{\'i}ez-Campelo and Carlo Finelli and Jurcic, \{Joseph G.\} and Greenberg, \{Peter L.\} and Sekeres, \{Mikkael A.\} and DeZern, \{Amy E.\} and Savona, \{Michael R.\} and Shetty, \{Jeevan K.\} and Rodrigo Ito and George Zhang and Xianwei Ha and Backstrom, \{Jay T.\} and Amit Verma",

note = "Funding Information: The study was supported by Celgene, a Bristol-Myers Squibb Company, in collaboration with Acceleron Pharma. Writing and editorial assistance were provided by James Matthews, PhD, of Excerpta Medica, funded by Bristol Myers Squibb. Funding Information: RSK: Advisory board fees from AbbVie, Acceleron, BMS, Geron, Jazz Pharmaceuticals, and Novartis; speakers{\textquoteright} bureau fees from BMS and Jazz Pharmaceuticals. UP: Grant support from Amgen, Janssen Biotech, Merck and Novartis; grant and travel support, and lecture, steering committee, and consulting fees, travel support from Celgene/BMS; and lecture fees from Novartis. PF: Consulting fees from Celgene. AMZ: Grant support, honoraria, clinical trial committee and consulting fees, from AbbVie, Celgene/BMS, and Novartis; consulting fees and honoraria from Acceleron, Agios, Astellas. Beyondspring, Cardinal Health, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Seattle Genetics, Syndax, Taiho, and Tyme; grant support from ADC Therapeutics, Astex and Medimmune/ AstraZeneca; grant support, consulting fees and honoraria from Amgen, Aprea, Boehringer-Ingelheim, Cardiff Oncology, Incyte, Otsuka, Pfizer, Takeda, and Trovagene; honoraria, consulting and clinical trial committee fees from Gilead and Kura; clinical trial committee fees from Geron. GG-M: Grant support and consulting fees from Astex Pharmaceuticals, BMS, Genentech, and Helsinn Healthcare; grant support from AbbVie, Amphivena Therapeutics, Aprea, Curis, Celgene, Forty Seven, H3 Biomedicine, Janssen, Merck, Novartis, and Onconova Therapeutics. GJM: Grant support from Celgene/BMS and Novartis. VS: Advisory board and lecture fees from Celgene/BMS; travel support from Janssen Biotech; advisory board fees from Geron, Gilead, Menarini, Novartis, and Takeda Oncology; grant support from Celgene. MD-C: Consulting fees from Celgene/BMS, Novartis, and Takeda. CF: Grant support, advisory committees, and speaker fees from Celgene/BMS; advisory committee and speaker fees from Novartis; consultancy from Takeda; advisory board fees from Janssen Pharmaceuticals. JGJ: Grant and travel support, and advisory board fees, AbbVie; grant support from Arog Pharmaceuticals, Astellas Pharma, Forma Therapeutics, Genentech USA, Gilead Sciences, PTC Therapeutics, and Syros Pharmaceuticals; advisory board fees from AstraZeneca; grant support, advisory board fees, and travel support from BMS/Celgene; grant support and consulting fees from Daiichi Sankyo; end-point committee fees from Novartis. PLG: Grant support from Celgene. MAS: Advisory boards for BMS, Gilead, Novartis, and Pfizer. AED: No competing financial interests. MRS: Steering committee and data and safety monitoring board fees from Celgene; consultancy and advisory for CTI, Geron, Karyopharm, Novartis, Ryvu, Taiho, Takeda, and TG Therapeutics; grant support from Astex, Incyte, Takeda, and TG Therapeutics; and equity in Karyopharm. JKS: Current employment at and equity in BMS. RI: Former employment and current equity in BMS; current employment and equity in Eli Lilly and Company. GZ and XH: Current employment at BMS. JTB: equity in BMS; current employment and equity in Acceleron Pharma. AV: Equity in Stelexis; consultancy and grant support from BMS; consultancy and honoraria from Acceleron Pharma; grant support from Janssen and Medpacto. ",

year = "2022",

month = may,

doi = "10.1038/s41375-022-01521-4",

language = "English (US)",

volume = "36",

pages = "1432--1435",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "5",

}

TY - JOUR

T1 - Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

AU - Komrokji, Rami S.

AU - Platzbecker, Uwe

AU - Fenaux, Pierre

AU - Zeidan, Amer M.

AU - Garcia-Manero, Guillermo

AU - Mufti, Ghulam J.

AU - Santini, Valeria

AU - Díez-Campelo, María

AU - Finelli, Carlo

AU - Jurcic, Joseph G.

AU - Greenberg, Peter L.

AU - Sekeres, Mikkael A.

AU - DeZern, Amy E.

AU - Savona, Michael R.

AU - Shetty, Jeevan K.

AU - Ito, Rodrigo

AU - Zhang, George

AU - Ha, Xianwei

AU - Backstrom, Jay T.

AU - Verma, Amit

N1 - Funding Information: The study was supported by Celgene, a Bristol-Myers Squibb Company, in collaboration with Acceleron Pharma. Writing and editorial assistance were provided by James Matthews, PhD, of Excerpta Medica, funded by Bristol Myers Squibb. Funding Information: RSK: Advisory board fees from AbbVie, Acceleron, BMS, Geron, Jazz Pharmaceuticals, and Novartis; speakers’ bureau fees from BMS and Jazz Pharmaceuticals. UP: Grant support from Amgen, Janssen Biotech, Merck and Novartis; grant and travel support, and lecture, steering committee, and consulting fees, travel support from Celgene/BMS; and lecture fees from Novartis. PF: Consulting fees from Celgene. AMZ: Grant support, honoraria, clinical trial committee and consulting fees, from AbbVie, Celgene/BMS, and Novartis; consulting fees and honoraria from Acceleron, Agios, Astellas. Beyondspring, Cardinal Health, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Seattle Genetics, Syndax, Taiho, and Tyme; grant support from ADC Therapeutics, Astex and Medimmune/ AstraZeneca; grant support, consulting fees and honoraria from Amgen, Aprea, Boehringer-Ingelheim, Cardiff Oncology, Incyte, Otsuka, Pfizer, Takeda, and Trovagene; honoraria, consulting and clinical trial committee fees from Gilead and Kura; clinical trial committee fees from Geron. GG-M: Grant support and consulting fees from Astex Pharmaceuticals, BMS, Genentech, and Helsinn Healthcare; grant support from AbbVie, Amphivena Therapeutics, Aprea, Curis, Celgene, Forty Seven, H3 Biomedicine, Janssen, Merck, Novartis, and Onconova Therapeutics. GJM: Grant support from Celgene/BMS and Novartis. VS: Advisory board and lecture fees from Celgene/BMS; travel support from Janssen Biotech; advisory board fees from Geron, Gilead, Menarini, Novartis, and Takeda Oncology; grant support from Celgene. MD-C: Consulting fees from Celgene/BMS, Novartis, and Takeda. CF: Grant support, advisory committees, and speaker fees from Celgene/BMS; advisory committee and speaker fees from Novartis; consultancy from Takeda; advisory board fees from Janssen Pharmaceuticals. JGJ: Grant and travel support, and advisory board fees, AbbVie; grant support from Arog Pharmaceuticals, Astellas Pharma, Forma Therapeutics, Genentech USA, Gilead Sciences, PTC Therapeutics, and Syros Pharmaceuticals; advisory board fees from AstraZeneca; grant support, advisory board fees, and travel support from BMS/Celgene; grant support and consulting fees from Daiichi Sankyo; end-point committee fees from Novartis. PLG: Grant support from Celgene. MAS: Advisory boards for BMS, Gilead, Novartis, and Pfizer. AED: No competing financial interests. MRS: Steering committee and data and safety monitoring board fees from Celgene; consultancy and advisory for CTI, Geron, Karyopharm, Novartis, Ryvu, Taiho, Takeda, and TG Therapeutics; grant support from Astex, Incyte, Takeda, and TG Therapeutics; and equity in Karyopharm. JKS: Current employment at and equity in BMS. RI: Former employment and current equity in BMS; current employment and equity in Eli Lilly and Company. GZ and XH: Current employment at BMS. JTB: equity in BMS; current employment and equity in Acceleron Pharma. AV: Equity in Stelexis; consultancy and grant support from BMS; consultancy and honoraria from Acceleron Pharma; grant support from Janssen and Medpacto.

PY - 2022/5

Y1 - 2022/5

UR - https://www.scopus.com/pages/publications/85125242726

UR - https://www.scopus.com/pages/publications/85125242726#tab=citedBy

U2 - 10.1038/s41375-022-01521-4

DO - 10.1038/s41375-022-01521-4

M3 - Article

C2 - 35220402

AN - SCOPUS:85125242726

SN - 0887-6924

VL - 36

SP - 1432

EP - 1435

JO - Leukemia

JF - Leukemia

IS - 5

ER -

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this